Table 3.
Pooled gastrointestinal adverse events associated with tirzepatide treatment in the SURPASS 1 and SURPASS 5 studies compared to comparator treatment in type 2 diabetes (54, 70, 75).
| Symptom | Tirzepatide 5 mg (total n = 237; % of subjects) | Tirzepatide 10 mg (total n = 240; % of subjects) | Tirzepatide 15 mg (total n = 241; % of subjects) | Placebo/comparator (total n = 235; % of subjects) |
|---|---|---|---|---|
| Nausea | 12 | 15 | 18 | 4 |
| Diarrhea | 12 | 13 | 17 | 9 |
| Decreased appetite | 5 | 10 | 11 | 1 |
| Vomiting | 5 | 5 | 9 | 2 |
| Constipation | 6 | 6 | 7 | 1 |
| Abdominal pain | 6 | 5 | 5 | 4 |